drug
linvoseltamab
Marketedupdated 5mo agoby $REGN REGENERON PHARMACEUTICALS, INC.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying linvoseltamab
- phase2A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
- phase2A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- phase3A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- phase2A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
- phase4Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- phase1A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- phase2A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
- phase2A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
News(5)
- GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750MAfter inking a T cell engager pact with Chimagen Biosciences a few years ago, GSK is back for more, this time acquiring a multiple myeloma program from the antibody specialist.biospace · 19d ago
- GSK doubles down on Chimagen with $750M multiple myeloma wagerGSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start phase 1 development of the multiple myeloma drug candidate next year. The de…fiercebiotech · 19d ago
- Trailing rivals, AbbVie scores win with dual-acting myeloma drugThe drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.biopharma_dive · 1mo ago
- AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma studyAbbVie’s etentamig has a relatively cleaner safety profile and an administration schedule that could give it an edge over other BCMA-targeting multiple myeloma therapies on the market, according to…biospace · 1mo ago
- Regeneron ends eye disease trial for anti-CD3 antibody following safety reviewRegeneron has hit the brakes on the phase 1/2a trial for an experimental eye inflammation treatment, following an adverse event that tilted the drug’s risk/benefit profile in the wrong direction.fiercebiotech · 1mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that